A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients
Status:
Completed
Trial end date:
2017-11-15
Target enrollment:
Participant gender:
Summary
The purpose of this study was to compare the development of new geographic atrophy in
patients with wet Age-related Macular Degeneration (AMD) when treated with either ranibizumab
or aflibercept over 24 months. Geographic atrophy is an advanced form of AMD that can result
in the progressive and irreversible loss of visual function over time.